Systems and methods for treating patients with processed lipoaspirate cells

• US 7,687,059 B2
• Filed: 10/20/2006
• Issued: 03/30/2010
• Est. Priority Date: 12/07/2001
• Status: Expired due to Fees

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H.
• Primary Examiner(s): LANKFORD JR, LEON B
• Application Number:
  US11/584,202
• Publication Number:
  US 20070036768A1
• Time in Patent Office: 1,257 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61B 10/0283 with vacuum aspiration, e.g. caused by retractable plunger or by connected syringe A61B10/025, A61B10/0266 take precedence
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61M 1/76 Handpieces specially for suction-irrigation A61M1/774, aspiration tips A61M1/84
• CPC Class Codes: A61M 2202/08 Lipoids
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12M 47/04 : Cell isolation or sorting purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04
• CPC Class Codes: C12N 2506/1384 : from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 : Vascular Endothelial cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Claims

1. A self contained adipose-derived stem cell processing unit, comprising:

a tissue collection container that is configured to receive unprocessed adipose tissue that is removed from a patient, wherein said tissue collection container is defined by a closed system;

a first filter that is disposed within said tissue collection container, wherein said first filter is configured to substantially retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter substantially separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises mature adipocytes;

a cell collection container, which is configured to receive said first component comprising a cell population that comprises adipose-derived stem cells from said tissue collection container, wherein said cell collection container is within said closed system;

a conduit configured to allow passage of said first component comprising a cell population comprising adipose-derived stem cells from said tissue collection container to said cell collection container while maintaining a closed system; and

a cell concentrator disposed within said cell collection container that is configured to facilitate the concentration of said first component comprising a cell population that comprises adipose-derived stem cells, wherein said cell concentrator comprises a centrifuge or a spinning membrane filter.

2. A method of using the self -contained adipose-derived stem cell processing unit of claim 1 to process a cell population that comprises adipose-derived stem cells, comprising:

removing adipose tissue that comprises a cell population that comprises adipose-derived stem cells from said patient;

introducing the removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells into the adipose-derived stem cell processing unit of claim 1; and

separating and concentrating said cell population that comprises adipose-derived stem cells from said removed adipose tissue within said self-contained adipose-derived stem cell processing unit while maintaining said closed pathway to obtain a concentrated cell population that comprises adipose-derived stem cells.

3. The method of claim 2, further comprising contacting said cell population that comprises adipose-derived stem cells with an additive.

4. The method of claim 2, further comprising mixing said concentrated cell population that comprises adipose-derived stem cells with a second portion of unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments from said patient.

5. The method of claim 2, further comprising cooling said concentrated cell population that comprises adipose-derived stem cells.

6. The method of claim 2, wherein said first portion of adipose tissue that is removed from said patient is lipoaspirate.

7. The method of claim 2, wherein said first portion of adipose tissue that is removed from said patient is obtained by excisional lipectomy.

8. The method of claim 4, wherein said second portion of adipose tissue that is removed from said patient is lipoaspirate.

9. The method of claim 4, wherein said second portion of adipose tissue that is removed from said patient is obtained by excisional lipectomy.

10. The method of claim 3, wherein said additive is a tissue or tissue fragment.

11. The method of claim 3, wherein said additive is demineralized bone.

12. The method of claim 3, wherein said additive is a compound of the thiaglitazone family.

13. The method of claim 3, wherein said additive is insulin.

14. The method of claim 3, wherein said additive is an exogenous DNA.

15. The method of claim 3, wherein said additive is a biological or artificial scaffold.

16. The method of claim 15, wherein said biological or artificial scaffold is a resorbable plastic sheath.

17. The method of claim 3, wherein said additive is an immunosuppressive agent.

18. The method of claim 17, wherein said immunosuppressive agent is selected from the group consisting of cyclosporine, myophenylate mofetil, rapamycin, and antithymocyte globulin.

19. The method of claim 3, wherein said additive is a cell differentiation agent.

20. The method of claim 19, wherein said cell differentiation agent is a cytokine.

21. The method of claim 19, wherein said cell differentiation agent is a growth factor.

22. The method of claim 3, wherein said additive is an antimicrobial agent.

23. The method of claim 2, further comprising mechanically or enzymatically disaggregating said removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells.

24. The method of claim 2, wherein said cell population comprising said adipose-derived stem cells is separated from mature adipocytes and connective tissue present in adipose tissue that was removed from said patient by employing a filter.

25. The adipose-derived stem cell processing unit of claim 1, wherein said cell concentrator comprises a spinning membrane filter.

26. The adipose-derived stem cell processing unit of claim 1, wherein said cell concentrator comprises an antibody.

27. The adipose-derived stem cell processing unit of claim 26, wherein said antibody is selected from the group consisting of AP2, CD3, CD19, and CD11 b.

28. The adipose-derived stem cell processing unit of claim 1, wherein said cell concentrator comprises a centrifuge.

29. The method of claim 23, wherein the removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells is enzymatically digested.

30. The method of claim 29, wherein said enzymatic digestion comprises a collagenase.

31. The method of claim 29, wherein said enzymatic digestion comprises a neutral protease.

32. The method of claim 29, wherein said enzymatic digestion comprises trypsin.

33. The method of claim 2, wherein said concentrated cell population that comprises adipose-derived stem cells comprises endothelial precursor cells.

34. The method of claim 5, wherein said cooling of said concentrated cell population that comprises adipose-derived stem cells is performed within said self-contained adipose-derived stem cell processing unit while maintaining a closed pathway.

35. The method of claim 5, wherein said concentrated cell population that comprises adipose-derived stem cells is cryopreserved.

36. The method of claim 3, wherein said additive is unprocessed adipose tissue that comprises intact, non-disaggregated tissue fragments.

37. The adipose-derived stem cell processing unit of claim 1, further comprising a temperature control device.

38. The adipose-derived stem cell processing unit of claim 37, wherein the temperature control device is configured to adjust the temperature of the components in the tissue collection container.

39. The adipose-derived stem cell processing unit of claim 37, wherein the temperature control device is configured to adjust the temperature of fluid that is delivered to the tissue collection container.

40. The adipose-derived stem cell processing unit of claim 1, further comprising a microprocessor configured to automate the self-contained adipose-derived stem cell processing unit.

41. The adipose-derived stem cell processing unit of claim 40, further comprising a temperature control device.

42. The self contained adipose-derived stem cell processing unit of claim 1, comprising an aspiration port coupled to a suction device.

43. The self contained adipose-derived stem cell processing unit of claim 1, wherein said second component comprises lipid.

44. The self contained adipose-derived stem cell processing unit of claim 1, wherein said second component comprises blood.

45. The self contained adipose-derived stem cell processing unit of claim 1, further comprising an outlet configured to allow the aseptic removal of said concentrated population of cells that comprises adipose-derived stem cells.